Graybill Wealth Management LTD. Purchases New Shares in Johnson & Johnson (NYSE:JNJ)

Graybill Wealth Management LTD. bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 28,457 shares of the company's stock, valued at approximately $4,719,000. Johnson & Johnson comprises 1.6% of Graybill Wealth Management LTD.'s investment portfolio, making the stock its 28th largest position.

Several other large investors also recently made changes to their positions in JNJ. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $29,000. Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $38,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.7%

Shares of NYSE:JNJ traded down $1.22 during trading on Thursday, hitting $163.56. 6,484,944 shares of the company were exchanged, compared to its average volume of 8,144,396. The stock has a market cap of $393.54 billion, a price-to-earnings ratio of 18.19, a P/E/G ratio of 2.12 and a beta of 0.41. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a fifty day moving average price of $153.95 and a two-hundred day moving average price of $154.71. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the company posted $2.82 EPS. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on JNJ. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Raymond James Financial dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Barclays raised their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday. Finally, Morgan Stanley raised their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday. Eleven research analysts have rated the stock with a hold rating, nine have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $174.11.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.